A multicenter, cohort controlled study comparing safety and efficacy of dolutegravir and elvitegravir-based regimens as switch strategies for HIV-infected patients.

Trial Profile

A multicenter, cohort controlled study comparing safety and efficacy of dolutegravir and elvitegravir-based regimens as switch strategies for HIV-infected patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Dec 2016

At a glance

  • Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Dolutegravir (Primary) ; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary) ; Emtricitabine/tenofovir (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top